Skip to main content
MedVellum
QuestionsVideosPricing

MedVellum

Fellowship exam preparation across every specialty: source-verified topics, questions in every format, and videos.

Product

  • Specialties
  • Questions
  • Videos
  • Exam tools
  • Pricing

Verification & policy

  • Verified register
  • Editorial policy
  • Privacy
  • Terms

Account

  • Sign in
  • Create account
  • Dashboard
  • Account & billing

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

llms.txtPsychiatry LLM catalogSitemap

O&G TopicsGynaecological health — menstrual disorders

O&G · Gynaecological health — menstrual disorders

Dysmenorrhoea and the PMS–PMDD spectrum: prostaglandin-mediated period pain and the luteal-phase psychiatric disorder

Also known as Dysmenorrhoea · Primary dysmenorrhoea · Secondary dysmenorrhoea · Premenstrual syndrome · PMS · Premenstrual dysphoric disorder · PMDD

Exam-exhaustive FRANZCOG fellowship topic on dysmenorrhoea and the premenstrual syndrome to premenstrual dysphoric disorder spectrum: primary dysmenorrhoea (prostaglandin-mediated, with the COX-PGF2α pathway read from source), secondary dysmenorrhoea (endometriosis, adenomyosis, fibroids, copper IUD), the PMS/PMDD spectrum with DSM-5 PMDD criteria reproduced verbatim, the symptom-free follicular phase signature, and the evidence-based management ladder (NSAID, COCP/progestin, LNG-IUS, SSRI continuous or luteal-phase, CBT, GnRH). RANZCOG-primary, globally tagged to MRCOG, ABOG, FRCSC and MRCPI.

high15 referencesUpdated 27 July 202614 min readVerification in progress

Practise this topic

  • 8 MCQs

Your progress

Saved on this device.

Practise this topic8 MCQs with explanations

Target exams

FRANZCOGMRCOGABOGFRCSCMRCPI

Red flags

  • Dysmenorrhoea that fails to respond to 3–6 months of adequate first-line therapy — investigate for a secondary cause (endometriosis, adenomyosis, submucous fibroid)
  • Dysmenorrhoea developing years after menarche and progressively worsening — secondary until proven otherwise
  • Severe dyspareunia, deep pain, abnormal bleeding or a pelvic mass — exclude endometriosis, adenomyosis or malignancy
  • Suicidal ideation in a woman with premenstrual symptoms — escalate to psychiatric assessment now; PMDD carries a substantial suicide risk
  • A woman with cyclical mood symptoms and a personal or family history of bipolar disorder — SSRIs can destabilise mood; psychiatry liaison first
  • Acute severe pelvic pain with syncope, fever or peritonism — exclude ectopic pregnancy, torsion or pelvic inflammatory disease before attributing to dysmenorrhoea
On this page
Study tools

Your progress

Saved on this device.

Practise this topic8 MCQs with explanations

Target exams

FRANZCOGMRCOGABOGFRCSCMRCPI

Red flags

  • Dysmenorrhoea that fails to respond to 3–6 months of adequate first-line therapy — investigate for a secondary cause (endometriosis, adenomyosis, submucous fibroid)
  • Dysmenorrhoea developing years after menarche and progressively worsening — secondary until proven otherwise
  • Severe dyspareunia, deep pain, abnormal bleeding or a pelvic mass — exclude endometriosis, adenomyosis or malignancy
  • Suicidal ideation in a woman with premenstrual symptoms — escalate to psychiatric assessment now; PMDD carries a substantial suicide risk
  • A woman with cyclical mood symptoms and a personal or family history of bipolar disorder — SSRIs can destabilise mood; psychiatry liaison first
  • Acute severe pelvic pain with syncope, fever or peritonism — exclude ectopic pregnancy, torsion or pelvic inflammatory disease before attributing to dysmenorrhoea
One-line fellowship answer

Dysmenorrhoea is painful menstrual cramping of uterine origin — primary in the absence of pathology (prostaglandin-mediated, treat with an NSAID, then a combined oral contraceptive or progestin, then a levonorgestrel intrauterine system) and secondary when associated with endometriosis, adenomyosis, fibroids, a copper intrauterine device or pelvic inflammatory disease (treat the cause). The premenstrual spectrum runs from premenstrual syndrome (PMS) to premenstrual dysphoric disorder (PMDD) — the defining signature is a symptom-free follicular phase, the DSM-5 requires at least five symptoms in the final week before menses with at least one being affective lability, irritability, depressed mood or anxiety, and first-line treatment is an SSRI (continuous or luteal-phase) with cognitive behavioural therapy and, second-line, an oral contraceptive.[1][8][9]

A 16-year-old misses school every month with cramping pain, and a 34-year-old dreads the week before her period because she becomes a person she does not recognise. The first has primary dysmenorrhoea; the second has PMDD. The two sit on the same clinic list because both are driven by the menstrual cycle — and both are under-recognised, under-treated and examinable. This topic covers the prostaglandin pathway of primary dysmenorrhoea, the causes of secondary dysmenorrhoea, the DSM-5 PMDD criteria reproduced verbatim, and the evidence behind every step of the ladder.[1][6][8]

Overview and definition

Dysmenorrhoea is painful menstrual cramping of uterine origin. It is the most common menstrual complaint and, in up to 20% of women, is severe enough to interfere with daily activities.[6]

  • Primary dysmenorrhoea — painful menstruation in the absence of pelvic pathology. It usually begins within 6 to 12 months of menarche, with spasmodic cramping lower abdominal pain starting just before or at the onset of menstruation and peaking in the first 24 to 72 hours, often with nausea, vomiting, diarrhoea, fatigue and headache.[6][7]
  • Secondary dysmenorrhoea — dysmenorrhoea associated with an organic or structural cause. It develops years after menarche (often in the third or fourth decade), is frequently progressive, may begin days before menses, and is accompanied by other features of the underlying disease (dyspareunia, abnormal bleeding, subfertility).[6]

The premenstrual disorders occupy a separate but adjacent spectrum, defined by timing: psychological and physical symptoms that develop in the luteal phase, cause functional impairment, and resolve shortly after the onset of menses. They are subdivided into premenstrual syndrome (PMS) and the more severe premenstrual dysphoric disorder (PMDD).[8][10]

Why this matters — the burden in numbers

up to 20%Women with dysmenorrhoea severe enough to interfere with daily activitiesschool and work absenteeism; quality-of-life impact
~80%Women with at least one luteal-phase symptombut most do not have significant impairment
~12%PMS prevalenceFrench population-based study; meets ACOG criteria
1.3–5.3%PMDD prevalenceWittchen 2002 community study; the severe end of the continuum
[6] [8]
Obstetrics & Gynaecology Pro

Continue reading

You have read the opening of this topic. The complete unit — every section and its primary-source references — is part of the Obstetrics & Gynaecology fellowship library.

Sign in to continueSee pricing
References15ShowHide
  1. [1]Marjoribanks J, Ayeleke RO, Farquhar C, Proctor M Nonsteroidal anti-inflammatory drugs for dysmenorrhoea. Cochrane Database Syst Rev, 2015.PMID 26224322
  2. [2]Dawood MY Dysmenorrhoea and prostaglandins: pharmacological and therapeutic considerations. Drugs, 1981.PMID 6790261
  3. [3]Dawood MY Nonsteroidal anti-inflammatory drugs and changing attitudes toward dysmenorrhea. Am J Med, 1988.PMID 3287908
  4. [4]Smith CA, Armour M, Zhu X, et al. Acupuncture for dysmenorrhoea. Cochrane Database Syst Rev, 2016.PMID 27087494
  5. [5]Pattanittum P, Kunyanone N, Brown J, et al. Dietary supplements for dysmenorrhoea. Cochrane Database Syst Rev, 2016.PMID 27000311
  6. [6]Latthe PM, Champaneria R, Khan KS Dysmenorrhoea. BMJ Clin Evid, 2011.PMID 21718556
  7. [7]American College of Obstetricians and Gynecologists' Committee on Adolescent Health Care ACOG Committee Opinion No. 760: Dysmenorrhea and Endometriosis in the Adolescent. Obstet Gynecol, 2018.PMID 30461694
  8. [8]Hofmeister S, Bodden S Premenstrual Syndrome and Premenstrual Dysphoric Disorder. Am Fam Physician, 2016.PMID 27479626
  9. [9]Marjoribanks J, Brown J, O'Brien PM, Wyatt K Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database Syst Rev, 2013.PMID 23744611
  10. [10]O'Brien PM, Bäckström T, Brown C, et al. Towards a consensus on diagnostic criteria, measurement and trial design of the premenstrual disorders: the ISPMD Montreal consensus. Arch Womens Ment Health, 2011.PMID 21225438
  11. [11]Nevatte T, O'Brien PM, Bäckström T, et al. ISPMD consensus on the management of premenstrual disorders. Arch Womens Ment Health, 2013.PMID 23624686
  12. [12]Ismaili E, Walsh S, O'Brien PMS, et al. Fourth consensus of the International Society for Premenstrual Disorders (ISPMD): auditable standards for diagnosis and management of premenstrual disorder. Arch Womens Ment Health, 2016.PMID 27378473
  13. [13]Endicott J, Nee J, Harrison W Daily Record of Severity of Problems (DRSP): reliability and validity. Arch Womens Ment Health, 2006.PMID 16172836
  14. [14]Lanza di Scalea T, Pearlstein T Premenstrual Dysphoric Disorder. Psychiatr Clin North Am, 2017.PMID 28477648
  15. [15]Lanza di Scalea T, Pearlstein T Premenstrual Dysphoric Disorder. Med Clin North Am, 2019.PMID 31078196

Test yourself

Practise what you just read

  • 8 MCQs
Obstetrics & Gynaecology Pro

$29/ monthor $279 / year

The complete Obstetrics & Gynaecology library, every exam format, one subscription.

  • Complete library for one chosen specialty
  • Timed MCQ mock exams and spaced review
  • Clinical cases & cross-table vivas
See pricingSign in
PreviousAdenomyosis: pathophysiology, MUSA imaging features & management (the A of PALM-COEIN)Gynaecological health — menstrual disordersNextEndometrial polyps: prevalence, malignant potential, PPP framework & hysteroscopic management (the P of PALM-COEIN)Gynaecological health — menstrual disorders